Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Contineum Therapeutics, Inc. (CTNM) had Free Cash Flow per Share of $-1.16 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-16.04M |
|
-- |
|
-- |
|
$17.90M |
|
$-17.90M |
|
$1.86M |
|
$-16.04M |
|
$-16.04M |
|
$-16.04M |
|
$-16.04M |
|
$-16.04M |
|
$-16.04M |
|
$-17.90M |
|
$-17.82M |
|
25.90M |
|
25.90M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$176.84M |
|
$0.86M |
|
$6.05M |
|
$182.89M |
|
$7.21M |
|
-- |
|
$4.28M |
|
$11.50M |
|
$171.39M |
|
$171.39M |
|
$171.39M |
|
25.92M |
|
| Cash Flow Statement Financials | |
$-30.07M |
|
$28.80M |
|
$0.12M |
|
$21.94M |
|
$20.78M |
|
$-1.16M |
|
$4.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
24.51 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-30.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.36% |
|
-9.36% |
|
-8.77% |
|
-9.36% |
|
$6.61 |
|
|
Free Cash Flow per Share |
$-1.16 |
$-1.16 |
|